What is Plus Therapeutics Debt-to-Equity?
Plus Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.10 Mil. Plus Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.09 Mil. Plus Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-1.35 Mil.
Plus Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -3.10.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Plus Therapeutics's Debt-to-Equity or its related term are showing as below:
PSTV'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4.46 Med: 1.21 Max: 10.32
Current: -3.1
During the past 13 years, the highest Debt-to-Equity Ratio of Plus Therapeutics was 10.32. The lowest was -4.46. And the median was 1.21.
Plus Therapeutics Debt-to-Equity Historical Data
The historical data trend for Plus Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics Debt-to-Equity Chart
|
Plus Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
10.32 |
2.31 |
0.65 |
0.88 |
-3.10 |
|
Plus Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.88 |
1.99 |
1.86 |
1.75 |
-3.10 |
Competitive Comparison of Plus Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Plus Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Debt-to-Equity falls into.
Plus Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Plus Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Plus Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics (Plus Therapeutics) Business Description
Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
| Marc H Hedrick |
officer: President |
C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
| Robert P Lenk |
director |
LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060 |
| Howard Clowes |
director |
217 DWIGHT ROAD, BURLINGAME CA 94010 |
| Greg Petersen |
director |
3100 MAIN STREET, SUITE 900, HOUSTON TX 77002 |
| Sims Andrew John Hugh Macintyre |
officer: Chief Financial Officer |
4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756 |
| Norman D. Lafrance |
officer: CHIEF MEDICAL OFFICER |
MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142 |
| Es-johansson An Van |
director |
6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
| Ag Postfinance |
10 percent owner |
MINGERSTRASSE 20, BERN V8 3030 |
| Bank Sa Swissquote |
10 percent owner |
CHEMIN DE LA CRETAUX 33, GLAND V8 1196 |
| Anthony Gregg Lapointe |
director |
PO BOX 83216, GAITHERSBURG MD 20883-3216 |
| Ron Martell |
director |
PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
| Mark Marino |
officer: Chief Medical Officer |
C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
| John David Harris |
officer: VP and GM of Cell Therapy |
3020 CALLAN ROAD, SAN DIEGO CA 92121 |
| Gail K Naughton |
director |
C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
| David Rickey |
director |
|
Plus Therapeutics (Plus Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PSTV has been successfully added to your